Gilead Sciences CEO Daniel O'Day Sells $35.6M in GILD Stock — Four Insiders Unload $42M

Gilead Sciences Chairman and CEO Daniel O'Day sold $35.6 million in GILD stock across 5 transactions in early 2026 — his largest selling window on record. Three other insiders added $6.4 million, bringing total insider selling to $42.02 million.

Four Insiders, $42M

Insider	Title	Transactions	Value	Shares After	Career Sales
Daniel O'Day	Chairman & CEO	5	$35.60M	556,698	$26.3M
Johanna Mercier	Chief Comm & Corp Aff Officer	5	$5.06M	103,221	$18.0M
Andrew Dickinson	Chief Financial Officer	2	$0.74M	150,503	$58.9M
Jeffrey Bluestone	Director	1	$0.62M	8,920	$2.5M
Total: 4 insiders			$42.02M

CEO O'Day's Record Sale

Daniel O'Day's $35.6 million sale actually exceeds his prior career total of $26.3 million — meaning this single selling window more than doubled his lifetime insider proceeds. He retains 556,698 shares worth approximately $62 million, so his remaining stake is still substantial.

O'Day joined Gilead as CEO in 2019 from Roche, inheriting a company in transition from its hepatitis C blockbuster era to a more diversified portfolio including HIV, oncology, and inflammation. His decision to sell $35.6M now — significantly more than any prior window — suggests a significant reassessment of his personal risk allocation.

CFO Dickinson: $58.9M Career Seller

CFO Andrew Dickinson is the quiet monster on this list. His $58.9 million in career sales far exceeds the CEO's cumulative total — making him one of the most prolific insider sellers in big pharma. His $740K sale in this round is modest relative to his history, but the career context tells the story: the person who manages Gilead's finances has been consistently monetizing for years.

Dickinson retains 150,503 shares (~$17M) — less than 30% of what he's sold over his career.

Chief Communications Officer Mercier: $18M Career

Johanna Mercier's $5.06M sale adds to her $18M career total. For a communications executive, $18M in lifetime insider sales is notable — she's monetized more than many C-suite leaders at smaller companies ever accumulate.

Gilead at ~$112: The HIV/Oncology Giant

Gilead Sciences is one of the world's largest biopharmaceutical companies, with dominant franchises in HIV treatment (Biktarvy), cell therapy (Yescarta), and a growing oncology pipeline. At ~$112 per share, the stock trades at approximately 12x forward earnings — a reasonable valuation by pharma standards.

• CEO doubled his career total in one shot: $35.6M vs $26.3M prior
• CFO is the biggest career seller: $58.9M lifetime
• 4 insiders, $42M total: Concentrated selling from the top
• Combined career: $105.7M from these four insiders

For GILD investors, the CEO's record sale is the headline. When the person running a $140 billion pharma company sells more stock in one window than in his entire prior tenure combined, it's a signal worth considering — especially from the leader whose compensation is tied to the stock's future performance.